Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DeepMatter Appoints Industry Advisors

16 Dec 2019 07:00

RNS Number : 8960W
DeepMatter Group PLC
16 December 2019
 

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

 

DeepMatter Appoints Industry Advisors

DeepMatter strengthens its depth of knowledge and industry links in Research & Medicinal Chemistry, Process Chemistry and Automation

 

16 December 2019 - DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is delighted to welcome three leading sector figures as industry advisors on its commercial roll-out of DigitalGlassware™. The advisors bring in-depth knowledge in research & medicinal chemistry, process chemistry and industrially focused closed-loop robotics and automation, all target industries for DigitalGlassware, the Company's innovative cloud-based digital chemistry platform that brings recordability, reproducibility and shareability to the lab.

 

The advisors will contribute to the ongoing development of the DigitalGlassware™ strategic roadmap and are as follows:

 

·; Dr Richard Bourne - a leading academic in Process Chemistry. Richard is Associate Professor at the University of Leeds based at the Institute of Process Research and Development, working on rapid process development and continuous flow chemistry. In November 2019, he was announced as a new Royal Academy of Engineering Senior Research Fellow in Digital Manufacturing and Discovery of Pharmaceuticals.

·; Dr John Harris - a pharmaceutical industry consultant with a wealth of research chemistry knowledge and expertise. John was previously Head of the Wellcome Foundation's UK cardiovascular therapeutic area and founder of BioFocus, a highly successful early-stage CRO, now part of the Charles River organisation.

·; Dr David M Parry - an experienced synthetic chemist, with a track record of delivering complex projects within the pharma and biotech sectors. David built and ran a business focused on automated medicinal chemistry, where compounds would be synthesised, then tested in a primary assay on the same platforms, with the results fed back into the software to inform the next round of automated synthesis.

 

Mark Warne, Chief Executive Officer of DeepMatter, commented:

"We believe DigitalGlassware™ has the opportunity to sit at the heart of the digitisation of chemistry, enabling chemists to produce better molecules, faster and ultimately cheaper. We are delighted to welcome Richard, John and David to the DigitalGlassware™ team, each bringing valuable insight from their three areas of specialism. Their expertise will help ensure the platform meets and integrates the needs of these key disciplines, assisting us in the commercial roll-out of our innovative cloud-based digital chemistry platform."

For more information, please contact:

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

 

 

 

 

Shore Capital (Nominated Adviser and Broker)

 

T: 020 7408 4050

Tom Griffiths

David Coaten

 

 

 

Alma PR

Caroline Forde

Jessica Joynson

Kieran Breheny

 

T: 020 3405 0205

deepmatter@almapr.co.uk

 

About DeepMatter Group plc

 

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors.

 

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.

 

Visit: www.deepmatter.io and follow @deepmattergroup

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMMMMZNFZGLZM
Date   Source Headline
24th Jan 20228:50 amRNSHolding(s) in Company
24th Jan 20227:00 amRNSHolding(s) in Company
20th Jan 202212:15 pmRNSResult of General Meeting
20th Jan 20227:00 amRNSResult of Open Offer - Correction
19th Jan 202211:30 amRNSResult of Open Offer
4th Jan 20221:30 pmRNSPosting of Circular and Notice of GM
29th Dec 20214:36 pmRNSPrice Monitoring Extension
24th Dec 20217:00 amRNSPlacing, Subscription and Open Offer
17th Dec 20215:00 pmRNSBusiness Update and Financing
22nd Oct 20217:00 amRNSAppointment of new Scientific Advisory Board
21st Oct 20218:00 amRNSDigitalGlassware® platform trial with Aurigene
28th Sep 20217:00 amRNSCollaboration
22nd Sep 20217:00 amRNSHalf Year Results
14th Sep 202110:30 amRNSNotice of Half Year Results
8th Sep 20211:30 pmRNSHolding(s) in Company
18th Aug 20217:00 amRNSAdvisory Board Appointment
5th Aug 20217:00 amRNSCollaboration with the University of Cambridge
12th Jul 20217:00 amRNSAppointment of Non-Executive Director
30th Jun 20213:34 pmRNSResult of AGM
22nd Jun 20217:00 amRNSChanges to 2021 AGM Arrangements
17th Jun 20217:00 amRNSCollaboration with the University of Leeds
8th Jun 20213:16 pmRNSPosting of ARA and Updated Notice of AGM
1st Jun 20217:00 amRNSFinal Results
24th May 20217:00 amRNSNotice of Results and Investor Presentation
6th May 20213:43 pmRNSHolding(s) in Company
7th Apr 20217:00 amRNSCollaboration with the University of Nottingham
11th Mar 20217:00 amRNSCo-distribution agreement with Elemental Machines
9th Mar 20217:00 amRNSDirectorate Change
20th Jan 20217:00 amRNSAgreement with Merck's Life Sciences business
19th Jan 20217:00 amRNSHolding(s) in Company
8th Jan 20212:00 pmRNSPrice Monitoring Extension
18th Dec 202010:30 amRNSGrant of PDMR Options
17th Dec 20207:00 amRNSMulti-year contract with Thieme Chemistry
26th Oct 202011:05 amRNSSecond Price Monitoring Extn
26th Oct 202011:00 amRNSPrice Monitoring Extension
21st Oct 20207:00 amRNSIssue of Shares and Total Voting Rights
19th Oct 20207:00 amRNSDirectorate Changes
16th Oct 20207:00 amRNSStrong adoption of ICSYNTH
2nd Oct 20202:05 pmRNSSecond Price Monitoring Extn
2nd Oct 20202:00 pmRNSPrice Monitoring Extension
1st Oct 20208:00 amRNSGrant of Options
29th Sep 20207:00 amRNSHolding(s) in Company
23rd Sep 20201:40 pmRNSHolding(s) in Company
22nd Sep 20204:29 pmRNSHolding(s) in Company
22nd Sep 20204:00 pmRNSHolding(s) in Company
22nd Sep 202010:32 amRNSHolding(s) in Company
15th Sep 20208:08 amRNSIssue of Shares and Total Voting Rights
10th Sep 20207:00 amRNSHalf-year Report
4th Sep 20208:26 amRNSHolding(s) in Company
3rd Sep 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.